Impact of HSA Cost Sharing Reductions on High-deductible Members with Diabetes
HSA 费用分摊减少对患有糖尿病的高免赔额会员的影响
基本信息
- 批准号:9039871
- 负责人:
- 金额:$ 45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-30 至 2020-09-29
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): High deductible health plans (HDHPs) have lower premiums, but require patients to pay the full cost of most medical care until annual deductibles of $1000 to $6000 are met. HDHPs have proliferated rapidly over the last decade. Health Savings Account (HSA)-qualified HDHPs are the most rapidly growing HDHP arrangement, now covering 14% of commercially insured Americans. These plans subject most health care services (including medications) to high annual deductibles but allow pre-tax contributions to accounts that can be used for medical costs. Advocates believe that exposing patients to greater costs will create "activated consumers" who will seek higher-value health care and adopt healthy behaviors, while critics fear that these economic barriers may reduce access to needed care. Our ongoing project in the Natural Experiments in Diabetes Translation (NEXT-D) initiative (5U58DP002719) has determined that diabetes patients with HSA-HDHPs experience the largest reductions in hospital access and adherence to key medications for chronic illness. Although these findings are concerning, federal regulations allow employers to tailor HSA-HDHPs through two mechanisms that could improve access to care: (1) Exempting certain chronic medications from deductible requirements (i.e., medications cost $0 to patients) through "preventive drug lists" ($0-PDs), and (2) Generously funding HSAs so that employees pay less out-of-pocket. Thus, HSA-HDHPs represent both a risk to diabetes patients but also an opportunity for employers to improve care through tailored cost sharing reductions. In this application, we will examine effects of these two important variations in HDHP design on diabetes secondary prevention, high priority care, diabetes complications, and costs, both overall and among vulnerable subgroups (men, low socioeconomic status, Black or Hispanic, severe diabetes, high comorbidity). We will employ a cutting-edge interrupted time series study design that approximates the estimates of randomized controlled trials. We will draw from a 12-year rolling cohort (2005-2017) of >60 million members insured by a large national health plan, with 30,000 diabetes patients who experience employer-mandated transitions to HSA-HDHPs. We will also conduct economic analyses from the employer and member perspectives of the impacts of $0-PDs and generously funded HSAs on total health care and out-of-pocket costs. Our findings will allow policy makers and employers to develop tailored, next-generation health insurance designs that optimize quality and equity for diabetes patients who are most vulnerable under HDHPs.
描述(由申请人提供):高免赔额健康计划(HDHPs)的保费较低,但要求患者支付大多数医疗护理的全部费用,直到满足每年1000美元至6000美元的免赔额。在过去十年中,高人权高专办迅速增加。健康储蓄账户(HSA)合格的HDHP是增长最快的HDHP安排,现在覆盖了14%的商业保险美国人。这些计划使大多数医疗保健服务(包括药物)每年都有很高的免赔额,但允许向可用于医疗费用的账户提供税前捐款。倡导者认为,让患者承担更高的费用将创造“激活的消费者”,他们将寻求更高价值的医疗保健并采取健康的行为,而批评者担心这些经济障碍可能会减少获得所需医疗服务的机会。我们正在进行的糖尿病转化自然实验(NEXT-D)项目(5 U 58 DP 002719)已经确定,患有HSA-HDHPs的糖尿病患者在医院就诊和坚持慢性病关键药物治疗方面的减少幅度最大。尽管这些发现令人担忧,但联邦法规允许雇主通过两种机制来定制HSA-HDHPs,这两种机制可以改善获得护理的机会:(1)免除某些慢性药物的免赔额要求(即,通过“预防药物清单”(0美元-PD),患者的药物成本为0美元),以及(2)慷慨资助HSA,以便员工支付更少的自付费用。因此,HSA-HDHPs对糖尿病患者来说既是一种风险,也是雇主通过定制成本分担减少来改善护理的机会。在本申请中,我们将研究HDHP设计中这两种重要变化对糖尿病二级预防、高优先级护理、糖尿病并发症和成本的影响,包括总体和弱势亚组(男性、低社会经济地位、黑人或西班牙裔、重度糖尿病、高合并症)。我们将采用一种尖端的中断时间序列研究设计,近似于随机对照试验的估计。我们将从一个由大型国家健康计划承保的超过6000万成员的12年滚动队列(2005-2017)中抽取,其中有30,000名糖尿病患者经历了雇主强制的HSA-HDHP过渡。我们还将从雇主和成员的角度对零美元PD和慷慨资助的HSAs对总医疗保健和自付成本的影响进行经济分析。我们的研究结果将使政策制定者和雇主能够开发量身定制的下一代健康保险设计,优化HDHPs下最脆弱的糖尿病患者的质量和公平性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dennis Ross-Degnan其他文献
Dennis Ross-Degnan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dennis Ross-Degnan', 18)}}的其他基金
Impact of HSA Cost Sharing Reductions on High-deductible Members with Diabetes
HSA 费用分摊减少对患有糖尿病的高免赔额会员的影响
- 批准号:
9137503 - 财政年份:2015
- 资助金额:
$ 45万 - 项目类别:
Evaluating Sequential Strategies to Reduce Readmission in a Diverse Population
评估减少不同人群再入院的序贯策略
- 批准号:
8295101 - 财政年份:2012
- 资助金额:
$ 45万 - 项目类别:
Evaluating Sequential Strategies to Reduce Readmission in a Diverse Population
评估减少不同人群再入院的序贯策略
- 批准号:
8434754 - 财政年份:2012
- 资助金额:
$ 45万 - 项目类别:
The Impact of Emerging Health Insurance Designs on Diabetes Outcomes and Disparit
新兴健康保险设计对糖尿病结果和差异的影响
- 批准号:
8712141 - 财政年份:2010
- 资助金额:
$ 45万 - 项目类别:
The Impact of Emerging Health Insurance Designs on Diabetes Outcomes and Disparit
新兴健康保险设计对糖尿病结果和差异的影响
- 批准号:
8133441 - 财政年份:2010
- 资助金额:
$ 45万 - 项目类别:
The Impact of Emerging Health Insurance Designs on Diabetes Outcomes and Disparit
新兴健康保险设计对糖尿病结果和差异的影响
- 批准号:
8510469 - 财政年份:2010
- 资助金额:
$ 45万 - 项目类别:
The Impact of Emerging Health Insurance Designs on Diabetes Outcomes and Disparit
新兴健康保险设计对糖尿病结果和差异的影响
- 批准号:
8324468 - 财政年份:2010
- 资助金额:
$ 45万 - 项目类别:
The Impact of Emerging Health Insurance Designs on Diabetes Outcomes and Disparit
新兴健康保险设计对糖尿病结果和差异的影响
- 批准号:
8065712 - 财政年份:2010
- 资助金额:
$ 45万 - 项目类别:
Race and Long-Term Diabetes Self-Management in an HMO
HMO 中的种族和长期糖尿病自我管理
- 批准号:
6685228 - 财政年份:2002
- 资助金额:
$ 45万 - 项目类别:
Race and Long-Term Diabetes Self-Management in an HMO
HMO 中的种族和长期糖尿病自我管理
- 批准号:
6620492 - 财政年份:2002
- 资助金额:
$ 45万 - 项目类别:
相似国自然基金
Hsa_circ_0034447通过调控NAT10介导的
mRNA ac4C修饰抑制食管鳞癌细胞凋亡的
机制研究
- 批准号:
- 批准年份:2025
- 资助金额:10.0 万元
- 项目类别:省市级项目
aPD-L1-HSA@SSK1纳米材料靶向诱导创面衰老中性粒细胞凋亡促进糖尿病创面愈合作用研究
- 批准号:2025JJ50484
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
长链非编码RNA-LINC02577通过hsa-miR-1270调控NUFIP1表达在结直肠癌生长转移中的作用及机制研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
黄芪通过hsa_circ_0004901-APAF1轴抑制血管内皮细胞焦亡改善糖尿病足血管内皮重构的研究
- 批准号:2025JJ81100
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
Hsa-miR-126-3p调控的TOPBP1/TICRR通过PD-1/PD-L1抑制CD8+ T细胞促进肝癌进展
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
冬凌草甲素通过调节 hnRNPA2B1/hsa_circ_402515/RSPO4-103aa/S100A8 轴重塑肿瘤相关巨噬细胞极化状态对胃癌侵袭转移的作用及机制研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
外泌体hsa_circ_0001240调控Rap1b/VEGFR2信号轴激活血管生成促进食管鳞癌发生发展的机制研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
hsa_circ_0008621介导的miR-300/SP1/MMP9轴在膀胱癌进展中的作用及分子机制研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
HUMSCs外泌体通过传递hsa-let-7a-5p调控支持细胞功能促进血睾屏障损伤修复的机制研究
- 批准号:JCZRYB202500883
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
hsa_circ_0014166在m6A修饰依赖条件下介导TP53 mRNA降解促进甲状腺癌淋巴结转移的作用及机制研究
- 批准号:JCZRYB202501174
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
相似海外基金
SBIR Phase II: High Surface Area (HSA) Intraluminal Cryoablation for the Treatment of High-Risk Patients with Gallstone Disease
SBIR II 期:高表面积 (HSA) 腔内冷冻消融治疗高危胆石病患者
- 批准号:
2214634 - 财政年份:2022
- 资助金额:
$ 45万 - 项目类别:
Cooperative Agreement
SBIR Phase I: High Surface Area (HSA) Intraluminal Cryoablation for the Treatment of High-risk Patients with Gallstone Disease
SBIR 第一期:高表面积 (HSA) 腔内冷冻消融治疗胆石病高危患者
- 批准号:
1938608 - 财政年份:2020
- 资助金额:
$ 45万 - 项目类别:
Standard Grant
Verification of the therapeutic effect improvement of BNCT brought about by MID-HSA administered with CED
验证MID-HSA与CED联合给药带来的BNCT治疗效果改善
- 批准号:
20K17945 - 财政年份:2020
- 资助金额:
$ 45万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Planning Grant: Engineering Research Center for Healthy and Safe Aging (ERC-HSA)
规划资助:健康安全老龄工程研究中心(ERC-HSA)
- 批准号:
1840358 - 财政年份:2018
- 资助金额:
$ 45万 - 项目类别:
Standard Grant
Involvement of hsa-miR-143 in podocyte injury by TGF-beta
hsa-miR-143 参与 TGF-β 足细胞损伤
- 批准号:
16K09601 - 财政年份:2016
- 资助金额:
$ 45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Functional role of hsa-miR-504 in airway inflammation and remodeling in asthma
hsa-miR-504 在哮喘气道炎症和重塑中的功能作用
- 批准号:
9284521 - 财政年份:2015
- 资助金额:
$ 45万 - 项目类别:
Functional role of hsa-miR-504 in airway inflammation and remodeling in asthma
hsa-miR-504 在哮喘气道炎症和重塑中的功能作用
- 批准号:
8803630 - 财政年份:2015
- 资助金额:
$ 45万 - 项目类别:
Impact of HSA Cost Sharing Reductions on High-deductible Members with Diabetes
HSA 费用分摊减少对患有糖尿病的高免赔额会员的影响
- 批准号:
9137503 - 财政年份:2015
- 资助金额:
$ 45万 - 项目类别:
Functional role of hsa-miR-504 in airway inflammation and remodeling in asthma
hsa-miR-504 在哮喘气道炎症和重塑中的功能作用
- 批准号:
9762966 - 财政年份:2015
- 资助金额:
$ 45万 - 项目类别:
Functional characterization of hsa-mir-939 as a novel regulator of pain
hsa-mir-939 作为新型疼痛调节剂的功能表征
- 批准号:
8626458 - 财政年份:2013
- 资助金额:
$ 45万 - 项目类别: